This indicates that the changes in LDLR epigenetic modifications in PBMCs proposed in our study can not only be used for disease risk monitoring in individuals at high risk for hypercholesterolemia, providing a new non-invasive monitoring tool for metabolic diseases [41], but may also become an effective environmental intervention target for potentially susceptible individuals. This evidence concerns the gene LDLR and familial hypercholesterolemia.